Small molecule inhibitors that target HIF2α can halt the transcription of key genes associated with the development of ccRCC, demonstrating targeted antitumor activity in mouse xenograft models [9]. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.